ArticleFrontiers in chemistry2020
Co-delivery of Salinomycin and Curcumin for Cancer Stem Cell Treatment by Inhibition of Cell Proliferation, Cell Cycle Arrest, and Epithelial-Mesenchymal Transition.
Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Hyaluronan like polysaccharide based nanodrugs with enhanced CD44 avidity for image-guided drug delivery to breast cancer.RSC advances · 2026Article
- Advanced drug delivery platforms target cancer stem cells.Asian journal of pharmaceutical sciences · 2025Review
- Curcumin for Treating Breast Cancer: A Review of Molecular Mechanisms, Combinations with Anticancer Drugs, and Nanosystems.Pharmaceutics · 2024Review
- Therapeutic vulnerabilities of cancer stem cells and effects of natural products.Natural product reports · 2023Review
- Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers.Pharmaceutics · 2023Review
- Nanomedicine strategies to counteract cancer stemness and chemoresistance.Exploration of targeted anti-tumor therapy · 2023Review
- Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy.International journal of nanomedicine · 2023Review
- Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review.Drug delivery · 2022Review
- Cancer Stem Cells and the Tumor Microenvironment: Targeting the Critical Crosstalk through Nanocarrier Systems.Stem cell reviews and reports · 2022Review
- Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review.Biomedicines · 2022Review
- Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy.International journal of nanomedicine · 2022Review
- M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer.Pharmaceutics · 2021Article
- Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant cancer is a devastating disease often associated with a poor clinical prognosis. For decades, modern drug discoveries have attempted to identify potential modulators that can impede tumor growth. Cancer stem cells however are more resistant to therapeutic intervention, which often leads to treatment failure and subsequent disease recurrence. Here in this study, we have developed a specific multi-target drug delivery nanoparticle system against breast cancer stem cells (BCSCs). Therapeutic agents curcumin and salinomycin have complementary functions of limiting therapeutic resistance and eliciting cellular death, respectively. By conjugation of CD44 cell-surface glycoprotein with poly(lactic-co-glycolic acid) (PLGA) nanoparticles that are loaded with curcumin and salinomycin, we investigated the cellular uptake of BCSCs, drug release, and therapeutic efficacy against BCSCs. We determined CD44-targeting co-delivery nanoparticles are highly efficacious against BCSCs by inducing G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.